269 related articles for article (PubMed ID: 31576684)
1. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
[TBL] [Abstract][Full Text] [Related]
2. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
3. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
Komatsu A; Igimi S; Kawana K
Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
[TBL] [Abstract][Full Text] [Related]
4. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
Alvarez RD; Huh WK; Bae S; Lamb LS; Conner MG; Boyer J; Wang C; Hung CF; Sauter E; Paradis M; Adams EA; Hester S; Jackson BE; Wu TC; Trimble CL
Gynecol Oncol; 2016 Feb; 140(2):245-52. PubMed ID: 26616223
[TBL] [Abstract][Full Text] [Related]
8. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
9. A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3.
Choi YJ; Hur SY; Kim TJ; Hong SR; Lee JK; Cho CH; Park KS; Woo JW; Sung YC; Suh YS; Park JS
Clin Cancer Res; 2020 Apr; 26(7):1616-1623. PubMed ID: 31727676
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study).
Ikeda Y; Uemura Y; Asai-Sato M; Nakao T; Nakajima T; Iwata T; Akiyama A; Satoh T; Yahata H; Kato K; Maeda D; Aoki D; Kawana K
Jpn J Clin Oncol; 2019 Sep; 49(9):877-880. PubMed ID: 31613356
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
12. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
[TBL] [Abstract][Full Text] [Related]
13. A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.
Hillemanns P; Denecke A; Woelber L; Böhmer G; Jentschke M; Schjetne KW; Bruins Slot KMH; Fredriksen AB
Clin Cancer Res; 2022 Nov; 28(22):4885-4892. PubMed ID: 36129459
[TBL] [Abstract][Full Text] [Related]
14. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.
Lichter K; Krause D; Xu J; Tsai SHL; Hage C; Weston E; Eke A; Levinson K
Obstet Gynecol; 2020 May; 135(5):1070-1083. PubMed ID: 32282601
[TBL] [Abstract][Full Text] [Related]
16. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
19. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.
Trimble CL; Peng S; Kos F; Gravitt P; Viscidi R; Sugar E; Pardoll D; Wu TC
Clin Cancer Res; 2009 Jan; 15(1):361-7. PubMed ID: 19118066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
